TY  - JOUR
TI  - Circulating Tumor DNA for Molecular Residual Disease Detection and Multicancer Early Detection: A Systematic Review
AU  - A.Sh. Ibrayeva
AU  - B.S. Asembekov
AU  - L.N. Ibragimova
AU  - M.M. Maemerov
AU  - D.K. Davletov
AU  - K.D. Kovaleva
JO  - Global Medical Reviews
PY  - 2026
DA  - 2026-07-27
VL  - 1
IS  - 1
SP  - e0004
KW  - circulating tumor DNA
KW  - ctDNA
KW  - liquid biopsy
KW  - molecular residual disease
KW  - multicancer early detection
KW  - MCED
AB  - Background: Circulating tumor DNA is clinically advanced in oncology, but its value differs between molecular residual disease assessment after curative-intent treatment and multicancer early detection in asymptomatic populations. Objective: To evaluate clinical effectiveness, actionability, and certainty of evidence for ctDNA-based MRD strategies and cfDNA- or ctDNA-based MCED pathways. Methods: The review followed PRISMA 2020 and PRISMA-S. Databases and trial registries were searched through July 2026. Two reviewers independently screened records, extracted data, and assessed risk of bias. Results: Twenty-nine completed reports representing 25 study programs were included. Selected MRD trials demonstrated clinical utility when test results were linked to defined treatment decisions. Conclusions: ctDNA has demonstrated clinical utility in selected MRD settings. In many other tumors it remains primarily prognostic, and broad MCED implementation is premature.
UR  - https://glr.sciences.kz/article/circulating-tumor-dna-mrd-mced
L2  - https://glr.sciences.kz/downloads/GMR_2026_1_1_e0004_circulating-tumor-dna-mrd-mced.pdf
ER  -